Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3018250 in Symptomatic Proximal Deep Vein Thrombosis
2023-503315-15-00Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in deep vein thrombosis (DVT) comparing BAY 3018250 with Placebo (2 arms). Primary endpoints: Area under the curve AUCn(6h-30d) of the ratio to baseline of clot burden and Composite of major and clinically relevant non-major bleeding events. Started Nov 2023; status: completed.
02
Drugs
inclocibart
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on 2023-503315-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503315-15-00.